Paraneoplastic Vision Loss Evaluation: Andrew McKeon, M,B., B.Ch., M.D. episode artwork

EPISODE · Feb 16, 2021 · 15 MIN

Paraneoplastic Vision Loss Evaluation: Andrew McKeon, M,B., B.Ch., M.D.

from Answers from the Lab · host Mayo Clinic Laboratories

(00:43) Could you please provide us with a little background on yourself, sir?  (01:05) So Dr. McKeon, can you just give us a brief overview on what this test is? (02:18) And you mentioned the CRMP-5 antibody and recoverin antibody. Are those the only two antibodies involved in this particular evaluation? (02:43) So those two antibodies, are they both tested up front ? And then, if so, are there any reflexes in this evaluation? (03:25) What will the results look like when a physician orders this test? Will they just get a positive or negative, or are there a titer levels that are more significant? Can you help us? (04:24) This testing, like a lot of our autoimmune testing, is going to confirm that diagnosis based on the patient presentation that you described just a few minutes ago. Is that right, sir? (05:21) Do you have any other advice on when physicians should be ordering this test? (06:25) So what testing is currently available on the market? Maybe you can explain that, and how is ours different than what's currently available?  (07:08) And why haven't we, sir? (07:40) I know recoverin is a brand new test for us. Is that also going to be available as a stand-alone where clients can order that? And then maybe, if so, could you elaborate on when that would be appropriate to order by itself? (08:45) Are there any other complementary tests that our audience should know about — maybe separate from autoimmune testing — that help to guide a diagnosis of paraneoplastic retinopathy or cancer-associated retinopathy? (09:58) I think that's really clear. But just to review, is the autoimmune testing ordered before those other tests, at the same time, or after?(10:29) I think a good place to end is how this testing is going to help patient care. Referring back to the struggles in this area with this patient population currently, and then how our test is going to be able to help direct a diagnosis or maybe prognosis and treatment. Can you talk about those things? (12:53) Are there any additional patient presentations that have been found with recoverin? (14:22) So if there are any questions about when to order this test or what to do with the results, they can really reach out to us anytime. Right, Dr. McKeon?  

Episode metadata supplied by the publisher feed · Published Feb 16, 2021

Embed this episode

Andrew McKeon, M,B., B.Ch., M.D., provides an overview of Mayo Clinic Laboratories' new paraneoplastic vision loss evaluation — a test that can help direct a cancer diagnosis and guide treatment. He reviews why this test was developed, when it should be ordered, and how the results can affect patient care.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Paraneoplastic Vision Loss Evaluation: Andrew McKeon, M,B., B.Ch., M.D.

0:00 15:18

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Answers from the Lab?

This episode is 15 minutes long.

When was this Answers from the Lab episode published?

This episode was published on February 16, 2021.

Can I download this Answers from the Lab episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!